Top Markets
#1 SuperVerse SuperVerse +20.75%
#2 Audiera Audiera +17.73%
#3 Win Win +15.98%
#4 Qkacoin Qkacoin +9.75%
#5 TRIA TRIA +7.94%
#6 Ontology Ontology +6.73%
#7 Shuffle Shuffle +6.73%
#8 Testicle Testicle +5.42%
#9 Hive Hive +4.90%
#10 Siren Siren +4.76%
Coin of the day
SuperVerse SuperVerse
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Novartis AG Novartis AG

Novartis AG

NVS
Classifica tra le azioni #46
Novartis AG researches, develops, manufactures, and markets healthcare products... Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Prezzo delle azioni
$150.75
Capitalizzazione di mercato
$291.41B
Variazione (1 giorno)
1.44%
Variazione (1 anno)
40.17%
Paese
CH
Scambia Novartis AG (NVS)

Categoria

Healthcare
Utile per Novartis AG (NVS)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Novartis AG, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Novartis AG dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Eli Lilly Eli Lilly
Eli Lilly
LLY.US
$25.73B -
US
AstraZeneca PLC AstraZeneca PLC
AstraZeneca PLC
AZN.US
$12.40B -
GB
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
$32.58B -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
$6.60B -
US
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
$21.07B -
US